

INNOVATION VENTURES

AVAILABLE TECHNOLOGIES

CONTACT US

Request Information

Permalink

A Novel Therapeutic Approach After a Heart Attack

Tech ID: 21646 / UC Case 2010-155-0

BACKGROUND

Myocardial infarction (MI) is a leading cause of cardiovascular diseases worldwide. There are five million people that suffer from heart failure in the United States alone at a cost of \$30 billion per year. MI often results in scar formation and death of contracting heart muscle cells (cardiomyocytes). The subsequent scarring of cardiomyocytes will permanently damage a patient's heart, leading to a life threatening heart rate disorder (arrhythmia). Despite therapeutic advances in heart disease, there are currently no treatments that can replace scarred cardiomyocytes with functional ones.

TECHNOLOGY DESCRIPTION

An investigator at the University of California, San Francisco, has identified a key target that allowed him to rescue cardiomyocytes from dying after a heart attack. This discovery has never been reported before and can potentially be developed as a novel therapeutic drug alone or in conjunction with other therapeutic agents in the treatment of patients after a heart attack or heart failure.

APPLICATIONS

Target can be developed as a novel therapeutic drug in patients that suffered a heart attack or heart failure

ADVANTAGES

- ▶ Target has been shown to rescue cardiomyocytes from dying after a heart attack
- ▶ To date, there are no competing products on the market to treat post heart attacks using this target

PATENT STATUS

Country	Туре	Number	Dated	Case
United States Of America	Issued Patent	9,084,761	07/21/2015	2010-155

RELATED MATERIALS

➤ Yeghiazarians Y, et al., IL-15: a novel prosurvival signaling pathway in cardiomyocytes. J Cardiovasc Pharmacol. 2014 May;63(5):406-11.

CONTACT

Ellen Kats

ellen.kats@ucsf.edu tel: 415-758-1598.



OTHER INFORMATION

KEYWORDS

Cardiovascular Disease,

Myocardial Infarction, Heart

Attack

CATEGORIZED AS

- **►** Medical
 - Disease:

Cardiovascular and

Circulatory System

Therapeutics

RELATED CASES

2010-155-0

ADDRESS

UCSF
Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco,CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax:

CONNECT

Follow in Connect

© 2011 - 2015, The Regents of the University

of California

Terms of use Privacy Notice